Metrics to compare | 7595 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship7595PeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.5x | −8.1x | −0.3x | |
PEG Ratio | −0.24 | −0.16 | 0.00 | |
Price/Book | 1.5x | 5.4x | 2.6x | |
Price / LTM Sales | 2.1x | 65.6x | 2.8x | |
Upside (Analyst Target) | - | 348.7% | 66.6% | |
Fair Value Upside | Unlock | −21.5% | 9.1% | Unlock |
Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers contract development and manufacturing organization; molecular diagnostic reagents; testing products, including pharmacogenomics, targeted therapy for cancer, disease risk assessment, and functional medicine services. In addition, it sells various platform, such as single-cell analysis platform / spatial gene expression; single-cell and spatial transcriptomics data analysis software; expert in mapping genomic structural variations; whole-genome precision annotation platform; single-cell and spatial transcriptomics data analysis software; precise immune cell identification; automated tissue dissociator; and clinical HLA testing platform. The company was founded in 2005 and is headquartered in Taipei, Taiwan.